Celera

News Celera

• QIAGEN and Celera Establish Distribution Agreement for Respiratory Pathogen Panel

  QIAGEN N.V. and Celera Corporation announced an agreement under which QIAGEN will distribute a Celera molecular multiplex assay. The assay is the next generation version of QIAGEN's ResPlex II assay for detection of respiratory pathogens. Multiplex assays allow testing for a multiple number of dif more

• Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.

  Enigma Diagnostics Limited announced that it has signed two patent license agreements with Roche Molecular Systems, Inc. (RMS). The licenses signed on15 July 2009, provide Enigma full access under patents owned or licensed by RMS and its affiliates to practice HybProbe real-time PCR chemistry and m more

• Lab21 signs a license with Celera for one of the first diagnostic tests for cirrhosis risk in hepatitis C patients

  Lab21 announced that it has obtained a licence from Celera, an Applera Corporation business, to provide access to its test for cirrhosis risk in patients with chronic hepatitis C viral (HCV) infection in the UK and Ireland. The test, known as CRS7, is the first clinical test capable of predicting t more

Publications Celera

• A de novo metagenomic assembly program for shotgun DNA reads

  Motivation: A high-quality assembly of reads generated from shotgun sequencing is a substantial step in metagenome projects. Although traditional assemblers have been employed in initial analysis of metagenomes, they cannot surmount the challenges created by the features of metagenomic data. Resu more

• Morphinome – A meta‐analysis applied to proteomics studies in morphine dependence

  Abstract This review is a meta‐analysis of data describing proteins regulated by morphine influence studied worldwide across last years administration. Up to date (July 2010), 15 studies concerning this subject have been published. Animal models, examined brain structures, the route of morphine a more

Market studies Celera

• Global In Vitro Diagnostics Market 2011-2015

  TechNavio's analysts forecast the Global In Vitro Diagnostics market to grow at a CAGR of 6.55 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing demand for biomarker-based tests worldwide. The Global In Vitro Diagnostics market has also be more

• Global Disease Management Solutions Market 2011-2015

  TechNavio's analysts forecast the Global Disease Management Solutions market to grow at a CAGR of 19.9 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing demand for medical assistance in the US. The Global Disease Management Solutions marke more

• Cepheid (CPHD) - Product Pipeline Analysis

  Cepheid (CPHD) - Product Pipeline Analysis Summary This report is a source for data, analysis and actionable intelligence on the Cepheid portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial p more

Websites Celera